Sei Investments Co. Acquires 14,379 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Sei Investments Co. boosted its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 7.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 197,806 shares of the biopharmaceutical company’s stock after purchasing an additional 14,379 shares during the quarter. Sei Investments Co. owned about 0.19% of Intra-Cellular Therapies worth $16,520,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. American Century Companies Inc. boosted its holdings in shares of Intra-Cellular Therapies by 25.3% during the 4th quarter. American Century Companies Inc. now owns 314,362 shares of the biopharmaceutical company’s stock worth $26,256,000 after buying an additional 63,423 shares during the period. Teacher Retirement System of Texas boosted its holdings in shares of Intra-Cellular Therapies by 18.2% during the fourth quarter. Teacher Retirement System of Texas now owns 28,159 shares of the biopharmaceutical company’s stock worth $2,352,000 after acquiring an additional 4,328 shares during the period. Xponance Inc. grew its position in shares of Intra-Cellular Therapies by 4.8% in the fourth quarter. Xponance Inc. now owns 13,609 shares of the biopharmaceutical company’s stock valued at $1,137,000 after purchasing an additional 628 shares during the last quarter. Natixis Advisors LLC increased its stake in shares of Intra-Cellular Therapies by 2.0% during the fourth quarter. Natixis Advisors LLC now owns 25,085 shares of the biopharmaceutical company’s stock worth $2,095,000 after purchasing an additional 502 shares during the period. Finally, Swiss National Bank lifted its holdings in Intra-Cellular Therapies by 0.8% during the 4th quarter. Swiss National Bank now owns 187,000 shares of the biopharmaceutical company’s stock worth $15,618,000 after purchasing an additional 1,500 shares during the last quarter. 92.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on ITCI shares. Piper Sandler reaffirmed a “neutral” rating and issued a $132.00 price objective (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Royal Bank of Canada reissued a “sector perform” rating and issued a $132.00 target price (up previously from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Baird R W lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Needham & Company LLC reissued a “hold” rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Finally, Leerink Partnrs cut shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Ten investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $106.08.

Intra-Cellular Therapies Stock Performance

Shares of ITCI stock opened at $131.75 on Friday. Intra-Cellular Therapies, Inc. has a fifty-two week low of $64.09 and a fifty-two week high of $131.79. The stock’s fifty day moving average price is $129.00 and its two-hundred day moving average price is $99.05. The company has a market cap of $14.01 billion, a PE ratio of -151.44 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The business had revenue of $199.22 million for the quarter, compared to the consensus estimate of $205.08 million. On average, equities analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.